Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 2

1(16.7%)

Phase 1

1(16.7%)

6Total

N/A(4)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06857448Not ApplicableNot Yet Recruiting

Autologous Point-of-Care Adipose Therapy: Recent Injury

Role: collaborator

NCT06857435Not ApplicableNot Yet Recruiting

Autologous Point-of-Care Adipose Therapy: Delayed Injury/Scar

Role: collaborator

NCT06747715Not ApplicableRecruiting

Autologous Fresh Fat Grafting Followed by Autologous Cryopreserved Fat Grafting

Role: collaborator

NCT03544632Phase 2Enrolling By Invitation

Acellular Adipose Tissue (AAT) for Soft Tissue Reconstruction

Role: collaborator

NCT00722280Not ApplicableTerminated

Human Upper Extremity (Hand and Forearm) Allotransplantation

Role: collaborator

NCT02482194Phase 1Completed

Autologous Mesenchymal Stem Cells Transplantation for Spinal Cord Injury- A Phase I Clinical Study

Role: collaborator

All 6 trials loaded